Work

Metatypical Metastatic Basal Cell Carcinoma Treated with Vismodegib: Report of Two Cases

Year: 2025

Type: article

Abstract: Background: Basal cell carcinoma (BCC) is a common type of skin cancer. Most of this tumors are mainly locally aggressive, but a very low percentage of patients can develop distant metastases (0.1%). Somatic mutations of PTCH1 were identified in over 70% of sporadic BCC. PTCH1 encodes a protein acting as a transmembrane receptor for the HH protein family, and vismodegib targets this mutation [1]. Basosquamous cell carcinoma is a rare subtype of BCC, that behaves aggressively [2]. The best treatment for basosquamous metastatic melanoma is yet unclear.

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2025.100322

Authors: D. Amarillo, V. Lemes, G. Krygier

Institutions: Universidad de la República de Uruguay, Hospital de Clínicas

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,340